
Shares of Lumos Diagnostics LDX.AX rise as much as 15.8% to A$0.22, their highest level since November 13
Healthcare diagnostics provider secures 100% medicare reimbursement recognition for FebriDx from all Medicare Administration Contractors at US$41.38 per test
FebriDx is a rapid point-of-care test that uses blood samples to aid in the differentiation between bacterial and non-bacterial infection
Shares up 514.3% YTD, including day's moves